mast cell leukemia

Summary

Summary: A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of >20% MAST CELLS, multi-organ failure and a short survival.

Top Publications

  1. ncbi Mast cell leukemia--a rare form of myeloid leukemia
    Peter Valent
    Wien Klin Wochenschr 114:173-4. 2002
  2. pmc Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
    Jason Gotlib
    Department of Medicine, Division of Hematology, Stanford University, Stanford Cancer Center, 875 Blake Wilbur Dr, Rm 2327B, Stanford, CA 94305 5821, USA
    Blood 106:2865-70. 2005
  3. ncbi Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation
    T Y Chen
    Division of Hematology Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
    Bone Marrow Transplant 32:111-4. 2003
  4. ncbi Malignant hematopoietic cell lines: in vitro models for the study of mast cell leukemia
    Hans G Drexler
    Leuk Res 27:671-6. 2003
  5. ncbi Synaptotagmin I expression in mast cells of normal human tissues, systemic mast cell disease, and a human mast cell leukemia cell line
    N Kimura
    Department of Pathology, Second Department of Internal Medicine, First Department of Pharmacology, Tohoku University, Sendai, Japan
    J Histochem Cytochem 49:341-6. 2001
  6. doi Mast cell leukemia: a report of ten cases
    Caterina Giovanna Valentini
    Ann Hematol 87:505-8. 2008
  7. ncbi Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras
    Xuecui Guo
    The Biomedical Research Centre, University of British Columbia, Vancouver, BC, Canada V6T1Z3
    Oncogene 24:2330-42. 2005
  8. pmc Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
    T Furitsu
    Second Department of Internal Medicine, Osaka University Medical School, Suita, Japan
    J Clin Invest 92:1736-44. 1993
  9. ncbi Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia
    Olaf Penack
    Ann Hematol 84:692-3. 2005
  10. pmc KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia
    Tomohiro Kajiguchi
    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1107, United States
    Leuk Res 32:761-70. 2008

Scientific Experts

Detail Information

Publications117 found, 100 shown here

  1. ncbi Mast cell leukemia--a rare form of myeloid leukemia
    Peter Valent
    Wien Klin Wochenschr 114:173-4. 2002
  2. pmc Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
    Jason Gotlib
    Department of Medicine, Division of Hematology, Stanford University, Stanford Cancer Center, 875 Blake Wilbur Dr, Rm 2327B, Stanford, CA 94305 5821, USA
    Blood 106:2865-70. 2005
    ..Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL)...
  3. ncbi Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation
    T Y Chen
    Division of Hematology Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
    Bone Marrow Transplant 32:111-4. 2003
    ..We report a case of acute myeloid leukemia (AML) with t(8;21) and mast cell leukemia (MCL) in which the mastocytosis persisted after standard chemotherapy and allogeneic stem cell ..
  4. ncbi Malignant hematopoietic cell lines: in vitro models for the study of mast cell leukemia
    Hans G Drexler
    Leuk Res 27:671-6. 2003
    ..group of entities characterized by abnormal proliferation and accumulation of mast cells, including mast cell leukemia. Progress in understanding the (patho)biology of mast cells has been hindered by the lack of genuine model ..
  5. ncbi Synaptotagmin I expression in mast cells of normal human tissues, systemic mast cell disease, and a human mast cell leukemia cell line
    N Kimura
    Department of Pathology, Second Department of Internal Medicine, First Department of Pharmacology, Tohoku University, Sendai, Japan
    J Histochem Cytochem 49:341-6. 2001
    ..The tumor cells of systemic mast cell disease (SMCD) and a human mast cell leukemia cell line (HMC-1) were also examined...
  6. doi Mast cell leukemia: a report of ten cases
    Caterina Giovanna Valentini
    Ann Hematol 87:505-8. 2008
  7. ncbi Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras
    Xuecui Guo
    The Biomedical Research Centre, University of British Columbia, Vancouver, BC, Canada V6T1Z3
    Oncogene 24:2330-42. 2005
    ..Thus, expression of either activated M-Ras or H-Ras in normal hematopoietic cells was sufficient for transformation but each resulted in the generation of distinct lineages of cells...
  8. pmc Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
    T Furitsu
    Second Department of Internal Medicine, Osaka University Medical School, Suita, Japan
    J Clin Invest 92:1736-44. 1993
    ..In a human mast cell leukemia cell line HMC-1, c-kitR was found to be constitutively phosphorylated on tyrosine, activated, and associated ..
  9. ncbi Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia
    Olaf Penack
    Ann Hematol 84:692-3. 2005
  10. pmc KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia
    Tomohiro Kajiguchi
    Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1107, United States
    Leuk Res 32:761-70. 2008
    ..KIT protein, are characteristic of human mast cell disease and are believed to play a central role in mast cell leukemia oncogenesis, proliferation and survival...
  11. ncbi RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demon
    Yi Yang
    Department of Medicine, Brigham and Women s Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:25756-74. 2002
    ..HMC-1 leukemia cells differentiated and underwent granule maturation when induced to express a normal form of RasGRP4. Thus, RasGRP4 plays an important role in the final stages of MC development...
  12. ncbi Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line
    Y Kanakura
    Department of Internal Medicine II, Osaka University Medical School, Suita, Japan
    Leukemia 8:S18-22. 1994
    ..In a human mast cell leukemia cell line (HMC-1), KitR was found to be constitutively phosphorylated on tyrosine, activated and associated ..
  13. ncbi Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells
    G H Schernthaner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Blood 98:3784-92. 2001
    Recent data suggest that mast cells (MCs) in patients with systemic mastocytosis or mast cell leukemia express a CD2-reactive antigen...
  14. ncbi Voltage-dependent and calcium-activated ion channels in the human mast cell line HMC-1
    S M Duffy
    Division of Respiratory Medicine, Institute for Lung Health, University of Leicester Medical School, Leicester, United Kingdom
    J Leukoc Biol 70:233-40. 2001
    ..We suggest that this current may contribute to the malignant phenotype while the Ca(2+)-activated K(+) and Cl(-) currents may be involved in cell activation...
  15. ncbi Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L)
    J H Jordan
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
    Hum Pathol 32:545-52. 2001
    ..serial bone marrow (bm) sections of 22 patients with mastocytosis (systemic indolent mastocytosis, n = 19; mast cell leukemia [MCL], n = 1; isolated bm mastocytosis, n = 2) were analyzed by immunohistochemistry using antibodies ..
  16. ncbi Moraxella catarrhalis induces mast cell activation and nuclear factor kappa B-dependent cytokine synthesis
    G Krishnaswamy
    Department of Internal Medicine, East Tennessee State University, Johnson City, Tennessee 37614 1709, USA
    Front Biosci 8:a40-7. 2003
    ..Human mast cell leukemia cells (HMC-1) were activated with either phorbol myristate acetate (PMA) and calcium ionophore or with ..
  17. ncbi Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature
    Alexander W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Leuk Res 28:249-57. 2004
    ..In one patient, progression to mast cell leukemia was seen after 3 months...
  18. ncbi Inhibition of trypsin-induced mast cell activation by water fraction of Lonicera japonica
    Ok Hwa Kang
    Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, Iksan, Jeonbuk 570 749, Korea
    Arch Pharm Res 27:1141-6. 2004
    ..However, LJ did not affect the trypsin activity even 1000 microg/mL. These results indicate that LJ may inhibit trypsin-induced mast cell activation through the inhibition of ERK phosphorylation than the inhibition of trypsin activity...
  19. ncbi [Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]
    Hans Peter Horny
    Institut fur Pathologie, Medizinische Universität zu Lübeck MUL, Lubeck
    Wien Klin Wochenschr 114:222-8. 2002
    ..While cutaneous mastocytosis is relatively frequent mast cell leukemia belongs to the rarest forms of human leukemia...
  20. ncbi Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930
    Filippo Petti
    OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Mol Cancer Ther 4:1186-97. 2005
    ..was used to selectively inhibit tyrosine phosphorylation downstream of juxtamembrane mutant Kit in the mast cell leukemia line HMC-1...
  21. ncbi Low back pain and myalgias in acute and relapsed mast cell leukemia: a case report
    Julie T Lin
    Department of Rehabilitation Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY 10021, USA
    Arch Phys Med Rehabil 83:860-3. 2002
    b>Mast cell leukemia is a rare, severe disease that may manifest through an array of clinical presentations, including vasomotor flushing and hypotension...
  22. ncbi Trypsin induces tumour necrosis factor-alpha secretion from a human leukemic mast cell line
    Ok Hwa Kang
    Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, Iksan, Chonbuk, 570 749, South Korea
    Cell Biochem Funct 21:161-7. 2003
    ..These results show that trypsin may induce TNF-alpha secretion following activation of ERK via both PAR2 and PAR4 on HMC-1 cells...
  23. ncbi [Systemic mastocytosis. Classification, symptoms, therapy]
    Doris M Kraemer
    Medizinische Poliklinik der Universität Würzburg, Wurzburg
    Med Klin (Munich) 99:131-6. 2004
    ..Systemic mastocytoses are a group of diseases, which are characterized by accumulation and unusual growth of mast cells infiltrating two different organs or types of tissue. Two case reports are introduced...
  24. ncbi CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking
    A W Hauswirth
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Int J Immunopathol Pharmacol 21:797-806. 2008
    ..SM with associated clonal hematologic non-MC-lineage disease (SM-AHNMD, n=6), aggressive SM (ASM, n=3), and mast cell leukemia (MCL, n=4). Surface expression of CD203c was analyzed by multicolor flow cytometry...
  25. ncbi Diagnostic value of tryptase in anaphylaxis and mastocytosis
    Lawrence B Schwartz
    Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Virginia Commonwealth University, PO Box 980263, McGuire Hall 4 110, Richmond, VA 23298, USA
    Immunol Allergy Clin North Am 26:451-63. 2006
    ..associated with a hematologic clonal non-mast cell disorder, aggressive systemic mastocytosis, and mast cell leukemia) and the decreased burden of mast cells associated with cytoreductive therapies in these disorders...
  26. ncbi Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells
    C I Smith
    Center for Biotechnology, Karolinska Institute, Novum, Huddinge, Sweden
    J Immunol 152:557-65. 1994
    ..in monocytes from healthy donors as well as in the human immature basophilic cell line KU812, in the human mast cell leukemia cell line HMC-1 and in the CD34 expressing myeloblast KG-1...
  27. ncbi Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
    Y Yamamoto
    Department of Infectious Diseases and the First Department of Internal Medicine, Nagoya University School of Medicine, Japan
    Blood 97:2434-9. 2001
    ..On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop...
  28. pmc Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1
    X Piao
    Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON Canada
    Proc Natl Acad Sci U S A 93:14665-9. 1996
    Activating mutations in the Kit receptor tyrosine kinase have been identified in both rodent and human mast cell leukemia. One activating Kit mutation substitutes a valine for aspartic acid at codon 816 (D816V) and is frequently observed ..
  29. ncbi Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs
    Puchit Samorapoompichit
    Institute of Histology and Embryology, The University of Vienna, Vienna, Austria
    Leuk Lymphoma 44:509-15. 2003
    b>Mast cell leukemia (MCL) is a rare disorder characterized by rapid disease progression, resistance against conventional cytoreductive drugs, and short survival...
  30. ncbi Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
    Cem Akin
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Exp Hematol 31:686-92. 2003
    ..Because activating mutations of c-kit affecting codon 816 are associated with human mast cell neoplasms, we determined whether STI571 exerted a similar cytotoxic effect on neoplastic and normal human mast cells...
  31. ncbi Chemotherapy for teratoma with malignant transformation
    Alessia C Donadio
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:4285-91. 2003
    ..We report that chemotherapy has a role in selected patients with MT, determined by cell type...
  32. ncbi Advanced mast cell disease: an Italian Hematological Multicenter experience
    Livio Pagano
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Rome, Italy
    Int J Hematol 88:483-8. 2008
    ..Twenty-four cases of advanced MCD were collected: 12 aggressive SM (50%), 8 mast cell leukemia (33%), 4 SM with associated clonal non-mast cell-lineage hematologic disease (17%)...
  33. pmc Selective RNAi-mediated inhibition of mutated c-kit
    Irene Ruano
    Centro de Biologia Molecular Severo Ochoa, CSIC UAM, Universidad Autonoma de Madrid, Departamento de Biologia Molecular, C Nicolás Cabrera, 1 Campus de Cantoblanco, Madrid, Spain
    J RNAi Gene Silencing 5:339-44. 2009
    ..Gain-of-function mutations in c-kit are one of the most characteristic events in mast cell leukemia (MCL) but as yet there is no clinically approved treatment for the disease...
  34. doi The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
    Philipp Erben
    III Medizinische Klinik, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Ann Hematol 93:81-8. 2014
    ..with associated hematological non-mast cell lineage disease (SM-AHNMD, n = 16, 11 %), and aggressive SM/mast cell leukemia ± AHNMD (ASM/MCL, n = 60, 41 %)...
  35. ncbi Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, , 1090 Vienna, Austria
    Leuk Res 25:529-36. 2001
    ..A percentage of MC>or=20% was invariably associated with the diagnosis 'mast cell leukemia'...
  36. doi Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor
    Sophie Georgin-Lavialle
    centre de référence des mastocytoses, Faculté de Médecine et AP HP Necker Enfants Malades, Paris, France
    Eur J Haematol 89:47-52. 2012
    ..Limited treatment options exist for mast cell leukemia, a rare form of systemic mastocytosis associated with a dire prognosis...
  37. doi Splicing the way to leukemia with KIT
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 49:1431-2. 2008
  38. ncbi 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells
    Gerard Fumo
    National Cancer Institute, Cell and Cancer Biology Branch, 9610 Medical Center Dr, Ste 300, Rockville, MD 20850, USA
    Blood 103:1078-84. 2004
    ..These data provide compelling evidence that 17-AAG may be effective in the treatment of c-kit-related diseases including mastocytosis, GISTs, mast cell leukemia, subtypes of acute myelogenous leukemia, and testicular cancer.
  39. ncbi Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia
    Shadmehr Demehri
    Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Exp Hematol 34:284-8. 2006
    Aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL) are rare but devastating diseases, for which no effective specific therapy is currently available...
  40. ncbi Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2
    Anja Vales
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Lymphoma 48:1997-2007. 2007
    ..leukemia (n = 14), chronic eosinophilic leukemia (n = 3), chronic myelomonocytic leukemia (n = 9), or mast cell leukemia/systemic mastocytosis (n = 3) as well as in respective cell lines...
  41. ncbi Clinical and biologic diversity of leukemias occurring in patients with mastocytosis
    W R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
    Leuk Lymphoma 37:473-86. 2000
    ..b>Mast cell leukemia (MCL) may also occur...
  42. ncbi Preformed angiotensin II is present in human mast cells
    Masatake Hara
    Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Cardiovasc Drugs Ther 18:415-20. 2004
    ..However, their function remains unclear. In this study, preformed angiotensin II (ANG II), a potent growth factor, was found to be contained in, and released by, human mast cells...
  43. ncbi Mast cell leukemia
    Peter Maslak
    Memorial Sloan Kettering Cancer Center, USA
    Blood 101:789. 2003
  44. ncbi Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies
    Pamela H Correll
    Department of Veterinary and Biomedical Sciences, Center for Molecular Immunology and Infectious Disease, The Pennsylvania State University, 115 Henning Building, University Park, PA 16802 3500, United States
    Gene 374:26-38. 2006
    ..activity in the Kit receptor, the Flt3 receptor, and the PDGFbeta/FGF1 receptors have been demonstrated in mast cell leukemia, acute myeloid leukemia (AML), and chronic myelogenous leukemias (CML), respectively...
  45. ncbi Flavones inhibit proliferation and increase mediator content in human leukemic mast cells (HMC-1)
    Michael Alexandrakis
    Department of Hematology, Medical Division, School of Health Sciences, University of Crete, Heraklion, Crete, Greece
    Eur J Haematol 71:448-54. 2003
    ..Some flavonoids, like quercetin, inhibit the growth of certain malignant cells in culture. Quercetin also inhibits histamine release and induces accumulation of secretory granules in rat basophilic leukemia cells...
  46. pmc Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive
    Magalie Joris
    Service d Hematologie, Centre Hospitalier Universitaire, Avenue Laennec, 80054 Amiens, France
    Case Report Hematol 2012:517546. 2012
    b>Mast cell leukemia (MCL) is a rare and aggressive disease with poor prognosis and short survival time...
  47. doi 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand
    Viviane Ghanim
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Blood 119:4242-52. 2012
    Aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL) are advanced hematopoietic neoplasms with poor prognosis. In these patients, neoplastic mast cells (MCs) are resistant against various drugs...
  48. ncbi The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus
    Lina Wang
    Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Gynecol Oncol 90:402-6. 2003
    ..C-kit expression has been identified in a number of different neoplasms that includes mastocytosis/mast cell leukemia, acute myeloblastic leukemia, seminoma/dysgerminoma, and gastrointestinal stromal tumors...
  49. doi The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis
    B Haenisch
    Institute of Human Genetics, University of Bonn, Bonn, Germany
    Immunol Res 56:155-62. 2013
    ..Whether this also holds true for systemic mast cell activation disease caused by other mutations in Kit or other mast cell activity-related genes is a subject for future studies...
  50. doi Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503
    Ning Ning Liu
    Department of Surgical Pathology, Hyogo College of Medicine, Nishinomiya, Japan
    Lab Invest 93:502-7. 2013
    ..at exon 9 has been reported in two cases of pediatric mastocytosis and one case of adult mast cell leukemia. Although KIT-Dup-Ser501Ala502 had not been reported in GISTs, we found two GIST cases possessing the ..
  51. doi Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:401-11. 2012
    ..Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extra-cutaneous organs...
  52. ncbi Mast cell histamine and cytokine assays
    David S Chi
    Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA
    Methods Mol Biol 315:203-15. 2006
    ..A human mast cell line (HMC-1), derived from a patient with mast cell leukemia, was activated with interleukin (IL)-1beta to study cytokine production and gene expression...
  53. pmc International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
    Jason Gotlib
    Stanford University School of Medicine, Stanford, CA
    Blood 121:2393-401. 2013
    ..The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced ..
  54. pmc Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V
    Karoline V Gleixner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Haematologica 98:1450-7. 2013
    Patients with advanced systemic mastocytosis, including mast cell leukemia, have a poor prognosis. In these patients, neoplastic mast cells usually harbor the KIT mutant D816V that confers resistance against tyrosine kinase inhibitors...
  55. ncbi Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells
    T Lasho
    Leukemia 24:1378-80. 2010
  56. doi Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia
    Rattanavalai Chantorn
    Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Pediatr Dermatol 29:605-9. 2012
    ..spectrum of the disease varies from only cutaneous lesions to highly aggressive systemic involvement such as mast cell leukemia. Mastocytosis can present from birth to adulthood...
  57. ncbi Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients
    A Pardanani
    Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 28:777-83. 2004
    ..MCD, 2 of 7 with MCD and an associated hematological disorder, and none of the 2 patients with either mast cell leukemia or smoldering systemic mastocytosis, expressed CD2...
  58. doi Stem cell factor contributes to tumorigenesis of mast cells via an autocrine/paracrine mechanism
    Y Amagai
    Cooperative Major in Advanced Health Science, Graduate School of Bio Applications and System Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan
    J Leukoc Biol 93:245-50. 2013
    ..the mutation is rarely observed in other forms of mastocytosis, such as cutaneous mastocytosis and mast cell leukemia/sarcoma, for which the mechanism of tumorigenesis remains unknown...
  59. pmc A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation
    Mi Hyun Bae
    Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
    Ann Lab Med 33:125-9. 2013
    ..metachromatic blasts strikingly proliferated during the state of bone marrow aplasia, and finally, aleukemic mast cell leukemia developed...
  60. doi Comprehensive mutational profiling in advanced systemic mastocytosis
    Juliana Schwaab
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Mannheim, Germany
    Blood 122:2460-6. 2013
    ..associated clonal hematologic nonmast cell lineage disorder (SM-AHNMD, n = 5), and aggressive SM (n = 15) or mast cell leukemia (n = 7) with (n = 18) or without (n = 4) AHNMD for additional molecular aberrations...
  61. ncbi Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder
    Gerhard J Molderings
    Institut fur Pharmakologie und Toxikologie, Universitatsklinikum Bonn, Germany
    Scand J Gastroenterol 42:1045-53. 2007
    ....
  62. pmc Mast cell transcriptional networks
    Clifford M Takemoto
    Division of Pediatric Hematology, The Johns Hopkins University, Baltimore, MD 21205, USA
    Blood Cells Mol Dis 41:82-90. 2008
    ..can result in a variety of diseases ranging from benign cutaneous mastocytosis to systemic mastocytosis or mast cell leukemia. Understanding mast cell differentiation provides important insights into mechanisms of lineage selection ..
  63. ncbi Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3
    T Tsujimura
    Department of Pathology, Osaka University Medical School, Japan
    Int Arch Allergy Immunol 106:377-85. 1995
    ..We have already shown the constitutive activation of c-kit receptor tyrosine kinase (KIT) in a human mast cell leukemia line (HMC-1) and a murine mastocytoma cell line (P-815)...
  64. ncbi Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
    Karoline V Gleixner
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Haematologica 92:1451-9. 2007
    In a majority of all patients with systemic mastocytosis (SM) including those with mast cell leukemia (MCL), neoplastic mast cells (MC) display the D816V-mutated variant of KIT...
  65. ncbi Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor
    Y Kitamura
    Department of Pathology, Osaka University Medical School, Japan
    Int Arch Allergy Immunol 107:54-6. 1995
    ..Signaling through the c-kit receptor tyrosine kinase (Kit) is essential for development and survival of mast cells but not of basophils. Moreover, we recently found an activation mutation of Kit in several tumor mast cell lines...
  66. ncbi Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis
    Uma N Sundram
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    J Cutan Pathol 34:289-95. 2007
    Cutaneous mast cell disorders are uncommon, but a subset, especially mastocytoma and mast cell leukemia, can histologically mimic myeloid leukemia cutis...
  67. ncbi Mastocytosis: state of the art
    Hans Peter Horny
    Institute of Pathology, Ansbach, Germany
    Pathobiology 74:121-32. 2007
    ..particular those with CM and ISM, remain in an indolent stage over many years or even decades, while others, in particular those with aggressive SM, SM-AHNMD, or mast cell leukemia, show a progressive course, usually with a fatal outcome.
  68. ncbi Effects of the Schisandra fructus water extract on cytokine release from a human mast cell line
    Ok Hwa Kang
    Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, Iksan, Jeonbuk, Republic of Korea
    J Med Food 9:480-6. 2006
    ..Taken together, these findings may help elucidate the mechanism of action of this medicine in the modulation of mast cell activation in inflammatory conditions...
  69. ncbi The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells
    Ozden Ozer
    Section of Hematopathology, Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 49:1567-77. 2008
    ..b>Mast cell leukemia (MCL) is the most aggressive mast cell neoplasm, but has not been well studied due to its rarity...
  70. ncbi The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation
    Yanli Jin
    Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat Sen University, Guangzhou, People s Republic of China
    Mol Cancer Ther 9:211-23. 2010
    ..The in vivo antitumor activity was evaluated by using the murine mast cell leukemia model...
  71. pmc Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V
    Christian Baumgartner
    Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
    Am J Pathol 175:2416-29. 2009
    ..Expression of pSTAT5 was also demonstrable in the KIT D816V-positive mast cell leukemia cell line HMC-1...
  72. ncbi Mast cell leukemia with rapidly progressing portal hypertension
    Masayuki Yoshida
    Department of Molecular Pathology and Tumor Pathology, Akita University Graduate School of Medicine, Akita, Japan
    Pathol Int 59:817-22. 2009
    Reported herein is an autopsy case of mast cell leukemia, a rare form of systemic mastocytosis, complicated with portal hypertension. A 52-year-old woman presented with urticaria-like skin symptoms, anemia, and thrombocytopenia...
  73. doi Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms
    Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    Leuk Lymphoma 52:740-4. 2011
    ..Finally, CD30 may be considered as a potential target of antibody-based therapeutic intervention in advanced mast cell disorders...
  74. ncbi Most common clinical presentations of cutaneous mastocytosis
    Vedrana Bulat
    University Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital, Zagreb, Croatia
    Acta Clin Croat 48:59-64. 2009
    ..patients with urticaria pigmentosa is extremely good, and over half of cases clear completely by adolescence, while those with aggressive systemic mastocytosis or mast cell leukemia show a progressive course, usually with a fatal outcome.
  75. doi Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
    Ken Hong Lim
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 113:5727-36. 2009
    ..clonal hematologic non-mast cell lineage disease (SM-AHNMD) in 138 (40%), aggressive (ASM) in 41 (12%), and mast cell leukemia in 4 (1%)...
  76. ncbi Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis
    P Valent
    Department of Internal Medicine, University of Vienna, Austria
    Blood 84:4322-32. 1994
    ..form of leukemic transformation has to be delineated from chronic myeloid leukemia with basophilia or basophil crisis, from primary mast cell leukemia, and from monocytic leukemias and myelodysplastic disorders associated with basophilia.
  77. doi Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis
    K J Aichberger
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
    Eur J Clin Invest 38:869-73. 2008
    ..Cladribine (2CdA) and dasatinib are two drugs that counteract the in vitro growth of neoplastic mast cells in SM. However, only little is known about the in vivo effects of these drugs in SM...
  78. ncbi Secretogranin III directs secretory vesicle biogenesis in mast cells in a manner dependent upon interaction with chromogranin A
    Prerna Prasad
    Center for Biomedical Research at The Queen s Medical Center, Honolulu, HI 96813, USA
    J Immunol 181:5024-34. 2008
    ..SgIII function in mast cells is unlikely to be limited to its partnership with CgA, as our interaction trap analysis suggests that SgIII has multiple binding partners, including the mast cell ion channel TRPA1...
  79. doi Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis
    Karl Sotlar
    Institute of Pathology, University of Munich, Munich, Germany
    Mod Pathol 24:585-95. 2011
    ..008). The mast cell leukemia cell line HMC-1, derived from a patient with aggressive systemic mastocytosis also expressed the CD30 ..
  80. ncbi Molecular genetics and development of mast cells: implications for molecular medicine
    M Fodinger
    Department of Laboratory Medicine, University of Vienna, Austria
    Mol Med Today 3:131-7. 1997
    ....
  81. ncbi Kit as a human oncogenic tyrosine kinase
    Y Kitamura
    Shionogi Pharmaceutical Company, 3 1 1 Futaba cho, Toyonaka, Osaka 561 0825, Japan
    Cell Mol Life Sci 61:2924-31. 2004
    ..The interrelationship between the type of Kit gain-of-function mutations and the therapeutic effect of imatinib mesylate has been well characterized in GISTs. Kit is interesting from both a biological and clinical view-point...
  82. ncbi Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI
    Arnold S Kirshenbaum
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Leuk Res 27:677-82. 2003
    ..Both LAD 1 and 2 release beta-hexosaminidase following FcepsilonRI or FcgammaRI aggregation. The availability of these cell lines offers an unparalleled circumstance to examine the biology of human mast cells...
  83. ncbi Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation
    A Spyridonidis
    Department of Haematology Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, Freiburg, Germany
    Bone Marrow Transplant 34:515-9. 2004
    b>Mast cell leukemia (MCL) is a rare form of aggressive mastocytosis with a reported median survival below 6 months. Casuistic reports suggest the effectiveness of allogeneic bone marrow transplantation (BMT) for MCL...
  84. ncbi ["Smoldering systemic mastocytosis. "Successful therapy with cladribine]
    V Schleyer
    Klinik und Poliklinik für Dermatologie der Universität Regensburg, Regensburg
    Hautarzt 55:658-62. 2004
    ..treated with antihistamines, glucocorticosteroids and PUVA therapy, the more aggressive forms, including mast cell leukemia, often require cytostatic chemotherapy...
  85. ncbi Inhibitory effect of retinoic acid on proliferation, maturation and tryptase level in human leukemic mast cells (HMC-1)
    M G Alexandrakis
    Department of Hematology, University of Crete School of Medicine, University Hospital of Herakleion, Crete, Greece
    Int J Immunopathol Pharmacol 16:43-7. 2003
    ..These results indicate that ATRA significantly inhibits both proliferation and growth as shown by the decreased intracellular tryptase levels in HMC-1. ATRA may be a useful agent in the treatment of mast cell proliferative disorders...
  86. ncbi Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells
    Marcus V M Andrade
    Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:7254-62. 2004
    ....
  87. ncbi Systemic mastocytosis: current concepts and treatment advances
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Curr Hematol Rep 3:197-202. 2004
    ..dysfunction), associated with another often chronic myeloid hematologic disease (SM-AHD), or present as mast cell leukemia or sarcoma. Mast cell-mediator symptoms are treated with histamine antagonists and cromolyn sodium...
  88. ncbi Monomeric IgE stimulates NFAT translocation into the nucleus, a rise in cytosol Ca2+, degranulation, and membrane ruffling in the cultured rat basophilic leukemia-2H3 mast cell line
    Vinita Pandey
    Department of Physiology, University College London, London, United Kingdom
    J Immunol 172:4048-58. 2004
    ..The mechanism of activation is likely to be via aggregation of the FcepsilonR1 because activation by IgE can be inhibited with monovalent hapten...
  89. ncbi Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis
    L Escribano
    Servicio de Hematologia, Mast Cell Unit, Hospital Ramon y Cajal, Carretera de Colmenar Km 9, 1, Madrid 28034, Spain
    Leuk Res 25:563-70. 2001
    ..Such observations would support the need to include the immunophenotypic analysis of MC in the diagnosis of mastocytosis...
  90. ncbi Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis
    P Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Leuk Res 25:595-602. 2001
    ..In contrast to true mast cell leukemia (MCL), MC do not form multifocal dense infiltrates in the bone marrow...
  91. ncbi Diagnostic criteria and classification of mastocytosis: a consensus proposal
    P Valent
    Department of Internal Medicine I, Division of Hematology, University of Vienna, Währinger Gürtel 18 20 Vienna, Austria
    Leuk Res 25:603-25. 2001
    ..clonal hematologic non-mast cell lineage disease (AHNMD), aggressive systemic mastocytosis (ASM), and mast cell leukemia (MCL). Patients with ISM usually have maculopapular skin lesions and a good prognosis...
  92. ncbi The isoflavone genistein inhibits proliferation and increases histamine content in human leukemic mast cells
    Michael G Alexandrakis
    Department of Hematology, University Hospital of Heraklion, School of Medicine, University of Crete, Greece
    Allergy Asthma Proc 24:373-7. 2003
    Mast cells are involved in allergic inflammation and some rare disorders such as systemic mastocytosis and mast cell leukemia. Certain naturally occurring flavonoids have been shown to inhibit mast cell activation and promote maturation ..
  93. ncbi Inhibitory effect of kaurane type diterpenoids from Acanthopanax koreanum on TNF-alpha secretion from trypsin-stimulated HMC-1 cells
    Xing Fu Cai
    College of Pharmacy, Chungnam National University, Daejeon 305 764, Korea
    Arch Pharm Res 26:731-4. 2003
    ..Among the isolated compounds 16alphaH,17-isovaleryloxy-ent-kauran-19-oic acid (1) showed potent inhibitory activity (IC50 value, 16.2 uM) on TNF-alpha secretion from HMC-1, a trypsin-stimulated human leukemic mast cell line...
  94. ncbi Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease
    Jin Young Baek
    Division of Hematopathology and Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 26:83-90. 2002
    ..type I TGF-beta receptor (TGFbeta1R) was not expressed in 30% of SMCD-HD patients or in patients with mast cell leukemia, but the remaining cases of MCD showed near uniform expression...
  95. ncbi The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy
    Girolamo Ranieri
    National Cancer Institute, Interventional Radiology Unit, Bari 70126, Italy
    Oncol Rep 10:1189-93. 2003
    ..These data indicate that angiogenesis and MCD are significantly correlated in MCTs progression...
  96. ncbi Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings
    H P Horny
    Institute of Pathology, Medical University of Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    Leuk Res 25:543-51. 2001
    ....
  97. ncbi Mastocytosis: pathology, genetics, and current options for therapy
    Peter Valent
    Department of Internal Medicine I, Medical Univeristy of Vienna, Austria
    Leuk Lymphoma 46:35-48. 2005
    ..SM (ISM), aggressive SM (ASM), SM with associated clonal hematological non-MC-lineage disease (AHNMD), and mast cell leukemia (MCL). The c-kit mutation D816V is quite common and may be found in all SM-categories...
  98. ncbi Pathogenesis, clinical features, and treatment advances in mastocytosis
    A Pardanani
    Division of Hematology, Mayo Clinic, Mayo Building W10A, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 19:595-615. 2006
    ..associated clonal hematological non-mast-cell disorder (SM-AHNMD), aggressive systemic mastocytosis (ASM), mast cell leukemia, and mast cell sarcoma...
  99. ncbi Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis
    Maria Theresa Krauth
    Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
    Hum Pathol 37:439-47. 2006
    ..Histidine decarboxylase should therefore be considered as a new MC marker in the screen panel of antigens used to diagnose high-grade MC malignancies...
  100. ncbi Analysis of the genes encoding the mast cell function-associated antigen and its alternatively spliced transcripts
    P Bocek
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    J Immunol 158:3235-43. 1997
    ..The transcription of the MAFA gene was detected in normal rat lungs, where both transmembranal and soluble MAFA appear to be expressed. Lung immunohistochemical analysis further suggests that MAFA expression is restricted to mast cells...
  101. ncbi Adrenomedullin in mast cells of abdominal aortic aneurysm
    Toshihiro Tsuruda
    First Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Japan
    Cardiovasc Res 70:158-64. 2006
    ..The purpose of this study was to examine the pathophysiological role of AM in the development of human abdominal aortic aneurysm (AAA)...

Research Grants62

  1. Oncogenic Kit receptor signaling in vivo
    Peter Besmer; Fiscal Year: 2010
    ..neoplasia oncogenic activation of Kit has roles in gastrointestinal stromal tumors (GIST), mastocytosis/mast cell leukemia, acute myelogenous leukemia, a subset of melanomas and a subset of germ cell tumors...
  2. Oncogenic Kit receptor signaling in vivo
    Peter Besmer; Fiscal Year: 2009
    ..neoplasia oncogenic activation of Kit has roles in gastrointestinal stromal tumors (GIST), mastocytosis/mast cell leukemia, acute myelogenous leukemia, a subset of melanomas and a subset of germ cell tumors...
  3. A Mouse Model for Human Gastrointestinal Stromal Tumor
    Peter Besmer; Fiscal Year: 2010
    ..In human neoplasia oncogenic activation of Kit has roles in gastrointestinal stromal tumors, mastocytosis/mast cell leukemia, acute myelogenous leukemia, a minor subset of melanomas and a subset of germ cell tumors...
  4. Mechanism of Normal and Ocogenic Kit Signaling in Vivo
    Peter Besmer; Fiscal Year: 2003
    ..In human neoplasia oncogenic activation of Kit is thought to have roles in mastocytosis/mast cell leukemia, acute myelogenous leukemia, gastro intestinal stromal tumors (GlST) and germ cell tumors...
  5. Mechanism of Normal and Ocogenic Kit Signaling in Vivo
    Peter Besmer; Fiscal Year: 2004
    ..In human neoplasia oncogenic activation of Kit is thought to have roles in mastocytosis/mast cell leukemia, acute myelogenous leukemia, gastro intestinal stromal tumors (GlST) and germ cell tumors...
  6. Mechanism of Normal and Ocogenic Kit Signaling in Vivo
    Peter Besmer; Fiscal Year: 2006
    ..In human neoplasia oncogenic activation of Kit is thought to have roles in mastocytosis/mast cell leukemia, acute myelogenous leukemia, gastro intestinal stromal tumors (GlST) and germ cell tumors...
  7. Mechanism of Normal and Ocogenic Kit Signaling in Vivo
    Peter Besmer; Fiscal Year: 2002
    ..In human neoplasia oncogenic activation of Kit is thought to have roles in mastocytosis/mast cell leukemia, acute myelogenous leukemia, gastro intestinal stromal tumors (GlST) and germ cell tumors...
  8. Mechanism of Normal and Ocogenic Kit Signaling in Vivo
    Peter Besmer; Fiscal Year: 2005
    ..In human neoplasia oncogenic activation of Kit is thought to have roles in mastocytosis/mast cell leukemia, acute myelogenous leukemia, gastro intestinal stromal tumors (GlST) and germ cell tumors...
  9. A Mouse Model for Human Gastrointestinal Stromal Tumor
    Peter Besmer; Fiscal Year: 2006
    ..activation of Kit is thought to have roles in gastro intestinal stromal tumors (GIST), mastocytosis/mast cell leukemia, acute myelogenous leukemia, and germ cell tumors...
  10. A Mouse Model for Human Gastrointestinal Stromal Tumor
    Peter Besmer; Fiscal Year: 2007
    ..activation of Kit is thought to have roles in gastro intestinal stromal tumors (GIST), mastocytosis/mast cell leukemia, acute myelogenous leukemia, and germ cell tumors...
  11. A Mouse Model for Human Gastrointestinal Stromal Tumor
    Peter Besmer; Fiscal Year: 2004
    ..activation of Kit is thought to have roles in gastro intestinal stromal tumors (GIST), mastocytosis/mast cell leukemia, acute myelogenous leukemia, and germ cell tumors...
  12. A Mouse Model for Human Gastrointestinal Stromal Tumor
    Peter Besmer; Fiscal Year: 2005
    ..activation of Kit is thought to have roles in gastro intestinal stromal tumors (GIST), mastocytosis/mast cell leukemia, acute myelogenous leukemia, and germ cell tumors...
  13. Cellular & Inflammatory Pathways in Ashtma & Allergic Diseases: From IgE to Cells
    Lawrence Schwartz; Fiscal Year: 2008
    ....
  14. Genetic networks that regulate the mast lineage
    Clifford Takemoto; Fiscal Year: 2006
    ..This proposal will provide insights into the mechanisms of lineage-selection during mast cell development and may lead to therapeutic targets for mast cell-related diseases. ..
  15. CHARACTERIZATION OF DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  16. Genetic networks that regulate the mast lineage
    Clifford Takemoto; Fiscal Year: 2005
    ..This proposal will provide insights into the mechanisms of lineage-selection during mast cell development and may lead to therapeutic targets for mast cell-related diseases. ..
  17. FTI Biology & Treatment of Myeloproliferative Disorders
    Jason Gotlib; Fiscal Year: 2005
    ..If clinically efficacious, further studies of R115777 in MPDs will be warranted...
  18. DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 1999
    ..A better understanding of mast cell development and activation in humans will provide a more precise understanding of their involvement in human disease, and better strategies for therapeutic interventions. ..
  19. BIOCHEMISTRY OF MAST CELL SECRETORY GRANULE ENZYMES
    Lawrence Schwartz; Fiscal Year: 2005
    ....
  20. EVALUATION OF BASOPHIL INVOLVEMENT IN HUMAN DISEASE
    Lawrence Schwartz; Fiscal Year: 2001
    ....
  21. Role of the STK Receptor in Erythropoiesis
    PAMELA CORRELL; Fiscal Year: 2006
    ....
  22. CHARACTERIZATION OF DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  23. Genetic networks that regulate the mast lineage
    Clifford Takemoto; Fiscal Year: 2007
    ..This proposal will provide insights into the mechanisms of lineage-selection during mast cell development and may lead to therapeutic targets for mast cell-related diseases. ..
  24. Role of the STK Receptor in Erythropoiesis
    Pamela Hankey; Fiscal Year: 2009
    ....
  25. Genetic networks that regulate the mast lineage
    Clifford Takemoto; Fiscal Year: 2009
    ..This proposal will provide insights into the mechanisms of lineage-selection during mast cell development and may lead to therapeutic targets for mast cell-related diseases. ..
  26. CHARACTERIZATION OF DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 2009
    ..abstract_text> ..
  27. Role of the STK Receptor in Erythropoiesis
    Pamela Hankey; Fiscal Year: 2008
    ....
  28. Genetic networks that regulate the mast lineage
    Clifford Takemoto; Fiscal Year: 2008
    ..This proposal will provide insights into the mechanisms of lineage-selection during mast cell development and may lead to therapeutic targets for mast cell-related diseases. ..
  29. Development of an Aging and Cancer Program at MSKCC
    George Bosl; Fiscal Year: 2007
    ..Through this planning grant, MSKCC will formally expand its research activities in cancer biology and management in the aging population so that it will become a key component of its NCI-funded CCSG. ..
  30. BIOCHEMISTRY OF MAST CELL SECRETORY GRANULE ENZYMES
    Lawrence Schwartz; Fiscal Year: 2004
    ....
  31. INDUCTION OF ATHEROGENESIS BY COCAINE AND HIV INFECTION
    Guha Krishnaswamy; Fiscal Year: 2000
    ..abstract_text> ..
  32. EVALUATION OF BASOPHIL INVOLVEMENT IN HUMAN DISEASE
    Lawrence Schwartz; Fiscal Year: 2000
    ....
  33. DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 2000
    ..A better understanding of mast cell development and activation in humans will provide a more precise understanding of their involvement in human disease, and better strategies for therapeutic interventions. ..
  34. INDUCTION OF ATHEROGENESIS BY COCAINE AND HIV INFECTION
    Guha Krishnaswamy; Fiscal Year: 1999
    ..abstract_text> ..
  35. CHARACTERIZATION OF DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 1993
    ....
  36. CHARACTERIZATION OF DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 1992
    ....
  37. CHARACTERIZATION OF DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 1991
    ....
  38. CHARACTERIZATION OF DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 1990
    ....
  39. DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 2001
    ..A better understanding of mast cell development and activation in humans will provide a more precise understanding of their involvement in human disease, and better strategies for therapeutic interventions. ..
  40. INDUCTION OF ATHEROGENESIS BY COCAINE AND HIV INFECTION
    Guha Krishnaswamy; Fiscal Year: 2001
    ..abstract_text> ..
  41. Role of the STK Receptor in Erythropoiesis
    PAMELA CORRELL; Fiscal Year: 2002
    ..abstract_text> ..
  42. DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 2003
    ..A better understanding of mast cell development and activation in humans will provide a more precise understanding of their involvement in human disease, and better strategies for therapeutic interventions. ..
  43. Role of the STK Receptor in Erythropoiesis
    PAMELA CORRELL; Fiscal Year: 2003
    ..abstract_text> ..
  44. Role of the STK Receptor in Erythropoiesis
    PAMELA CORRELL; Fiscal Year: 2002
    ..abstract_text> ..
  45. MURINE STK RECEPTOR AND MACROPHAGE ACTIVATION
    PAMELA CORRELL; Fiscal Year: 2002
    ..By understanding, in more detail, the regulation of macrophage activation, the PI hopes to begin to identify targets for suppression of the tissue-damaging effects of inflammation without compromising the host immune response. ..
  46. DIFFERENT TYPES OF HUMAN MAST CELLS
    Lawrence Schwartz; Fiscal Year: 2002
    ..A better understanding of mast cell development and activation in humans will provide a more precise understanding of their involvement in human disease, and better strategies for therapeutic interventions. ..
  47. BIOCHEMISTRY OF MAST CELL SECRETORY GRANULE ENZYMES
    Lawrence Schwartz; Fiscal Year: 2002
    ....
  48. MECHANISM OF ACTION OF FOLATE ANTAGONISTS
    George Bosl; Fiscal Year: 2002
    ....